Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buyi Qiangxin tablets is a traditional Chinese patent medicine formulated for the treatment of chronic heart failure. It is composed of six active herbal ingredients: *Panax ginseng* (ginseng), *Astragalus membranaceus* (huangqi), *Periploca sepium* (xiangjiapi), *Salvia miltiorrhiza* (danshen), *Ophiopogon japonicus* (maidong), and *Lepidium apetalum* (tinglizi). The formulation is designed to replenish qi, nourish yin, promote blood circulation, and induce diuresis to alleviate edema. It is primarily indicated for patients with chronic congestive heart failure (NYHA class II-III) presenting with qi and yin deficiency accompanied by blood stasis and water retention. Clinical trials, including those sponsored by Tianjin University of Traditional Chinese Medicine, have evaluated its efficacy and safety when integrated with standard Western medical therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buyi Qiangxin tablets.